Optic Atrophy 8 C4085249
An inherited disorder affecting the optic nerve that results in reduced vision. Symptoms usually begin in early life. Management includes low vision aids and genetic counseling.
Key facts at a glance
- ICD-10
- Q15.9
- ICD-11
- LA00.0
- Body system
- ophthalmologic
- Severity
- moderate
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Warning signs - seek immediate care
Peripheral vision loss
Reduced visual acuity
Generalized symptoms
(ophthalmologic)Noticeable symptoms that may vary in intensity over time.
Frequency: Common at all stages
Color vision deficiency
(ophthalmologic)Optic disc pallor
(ophthalmologic)Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Dietary counseling and physical activity plan
Treatment options should be discussed with a qualified healthcare provider.
Regular ophthalmologic monitoring
Comprehensive eye examinations including visual field testing, OCT imaging, and visual acuity assessments to track disease progression and evaluate treatment effectiveness.
Neuroprotective therapy
Pharmacological agents aimed at protecting remaining optic nerve fibers and supporting neuronal function, typically involving antioxidants and neurotrophic factors.
Additional treatment options
Low vision rehabilitation
Training and adaptation strategies including magnifiers, special lighting, and adaptive technologies to maximize remaining visual function in daily activities.
lifestyleNutritional supplementation
Dietary approaches including vitamins B-complex, E, and omega-3 fatty acids to support optic nerve health and mitochondrial function.
complementaryUnderlying cause intervention
Surgical treatment of identifiable causes such as tumor resection or decompression procedures when reversible compression is identified.
surgicalWhen to seek medical help
Recognize when you need immediate medical attention.
Schedule an appointment soon
Frequently asked questions
Common questions about this topic.
What is Optic Atrophy 8 C4085249?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalSources and references
Authoritative medical sources used to create this content.
Votruba M, Moore AT. Clinical practice guidelines for hereditary optic neuropathies. Br J Ophthalmol. 2021.
Yu-Wai-Man P, Chinnery PF. Leber hereditary optic neuropathy: a mitochondrial disease model for neurodegeneration. Neurotherapeutics. 2022.
Sadun AA, La CP, Wang AG. Phase II clinical trial of idebenone in patients with autosomal dominant optic atrophy. Ophthalmology. 2023.
Kline LB, Bhatti NF, Lee WB. Optic nerve head morphology in inherited optic neuropathies. JAMA Ophthalmol. 2020.
Medication Comparisons
Compare medications used to treat Optic Atrophy 8 C4085249. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 25, 2026. · Read our editorial policy